Investments
27Funds
1Partners & Customers
10Service Providers
1About AstraZeneca
AstraZeneca (LON: AZN) is a biopharmaceutical company. It focuses on the discovery, development, manufacturing, distribution and worldwide commercialization of primary care and specialty care medicines. The company was founded in 1999 and is based in Cambridge, U.K.
Want to inform investors similar to AstraZeneca about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing AstraZeneca
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find AstraZeneca in 4 Expert Collections, including Digital Health.
Digital Health
460 items
Companies developing and enabling evidence-based, software-driven therapeutic interventions to prevent, manage, or treat a medical disorder or disease. (*Scope follows the Digital Therapeutics Alliance definition)
Synthetic Biology
382 items
Diabetes
1,903 items
Biopharma Tech
260 items
Research containing AstraZeneca
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned AstraZeneca in 22 CB Insights research briefs, most recently on Oct 28, 2022.
Latest AstraZeneca News
Jan 29, 2023
New York, New York, UNITED STATES NEW YORK, Jan. 29, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: CinCor Pharma, Inc. (NASDAQ: CINC)’s sale to AstraZeneca for $26.00 per share in cash at closing, plus a non-tradable contingent value right of $10.00 per share in cash payable upon a specified regulatory submission of a baxdrostat product. If you are a CinCor shareholder, click here to learn more about your rights and options . Per the terms of the proposed transaction, Ipsen would acquire Albireo for $42.00 per share in cash plus one contingent value right per share (CVR), entitling its holder to deferred cash payments of $10.00 per CVR payable upon the U.S. Food and Drug Administration’s approval of Bylvay in the Biliary Atresia indication by December 31, 2027. If you are an Albireo shareholder, click here to learn more about your rights and options .
AstraZeneca Investments
27 Investments
AstraZeneca has made 27 investments. Their latest investment was in Doctor.One as part of their Grant on August 8, 2022.
AstraZeneca Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
8/1/2022 | Grant | Doctor.One | $0.09M | Yes | 1 | |
3/23/2022 | Corporate Minority | Huma | $33M | Yes | 2 | |
11/16/2021 | Series B - III | Gaoguang Pharmaceutical | $15.68M | Yes | 1 | |
9/23/2021 | Corporate Minority | |||||
9/16/2020 | Series A |
Date | 8/1/2022 | 3/23/2022 | 11/16/2021 | 9/23/2021 | 9/16/2020 |
|---|---|---|---|---|---|
Round | Grant | Corporate Minority | Series B - III | Corporate Minority | Series A |
Company | Doctor.One | Huma | Gaoguang Pharmaceutical | ||
Amount | $0.09M | $33M | $15.68M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | |||||
Sources | 1 | 2 | 1 |
AstraZeneca Acquisitions
19 Acquisitions
AstraZeneca acquired 19 companies. Their latest acquisition was CinCor Pharma on January 09, 2023.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
1/9/2023 | Series B | $193M | Acq - Pending | 1 | ||
11/29/2022 | Series A | $125M | Acquired | 38 | ||
7/5/2022 | Acquired | 13 | ||||
7/21/2021 | Other | |||||
12/17/2015 | Series B |
Date | 1/9/2023 | 11/29/2022 | 7/5/2022 | 7/21/2021 | 12/17/2015 |
|---|---|---|---|---|---|
Investment Stage | Series B | Series A | Other | Series B | |
Companies | |||||
Valuation | |||||
Total Funding | $193M | $125M | |||
Note | Acq - Pending | Acquired | Acquired | ||
Sources | 1 | 38 | 13 |
AstraZeneca Fund History
1 Fund History
AstraZeneca has 1 fund, including AstraZeneca Fund.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
2/14/2020 | AstraZeneca Fund | $229M | 1 |
Closing Date | 2/14/2020 |
|---|---|
Fund | AstraZeneca Fund |
Fund Type | |
Status | |
Amount | $229M |
Sources | 1 |
AstraZeneca Partners & Customers
10 Partners and customers
AstraZeneca has 10 strategic partners and customers. AstraZeneca recently partnered with AIM ImmunoTech on January 1, 2023.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
1/17/2023 | Partner | United States | 2 | ||
1/11/2023 | Partner | United Kingdom | AstraZeneca’s Airsupra gets US approval as new rescue treatment for asthma The co-development partnership between AstraZeneca and Avillion LLP has recently expanded to include the BATURA study , a randomized phase IIIb decentralized trial to further assess the role of Airsupra in reducing the risk of asthma exacerbations . | 3 | |
1/5/2023 | Partner | United States | Tempus, AstraZeneca Collaborate on Response Biomarker Discovery for Small Cell Lung Cancer NEW YORK -- Tempus said Thursday that it is collaborating with AstraZeneca on a prospective clinical study to identify biomarkers of response in small cell lung cancer patients . | 1 | |
1/5/2023 | Partner | ||||
12/21/2022 | Partner |
Date | 1/17/2023 | 1/11/2023 | 1/5/2023 | 1/5/2023 | 12/21/2022 |
|---|---|---|---|---|---|
Type | Partner | Partner | Partner | Partner | Partner |
Business Partner | |||||
Country | United States | United Kingdom | United States | ||
News Snippet | AstraZeneca’s Airsupra gets US approval as new rescue treatment for asthma The co-development partnership between AstraZeneca and Avillion LLP has recently expanded to include the BATURA study , a randomized phase IIIb decentralized trial to further assess the role of Airsupra in reducing the risk of asthma exacerbations . | Tempus, AstraZeneca Collaborate on Response Biomarker Discovery for Small Cell Lung Cancer NEW YORK -- Tempus said Thursday that it is collaborating with AstraZeneca on a prospective clinical study to identify biomarkers of response in small cell lung cancer patients . | |||
Sources | 2 | 3 | 1 |
AstraZeneca Service Providers
1 Service Provider
AstraZeneca has 1 service provider relationship
Service Provider | Associated Rounds | Provider Type | Service Type |
|---|---|---|---|
Acq - P2P | Investment Bank | Financial Advisor |
Service Provider | |
|---|---|
Associated Rounds | Acq - P2P |
Provider Type | Investment Bank |
Service Type | Financial Advisor |
Partnership data by VentureSource
AstraZeneca Team
83 Team Members
AstraZeneca has 83 team members, including current Chief Executive Officer, Pascal Soriot.
Name | Work History | Title | Status |
|---|---|---|---|
Pascal Soriot | Roche Holding, and Genentech | Chief Executive Officer | Current |
Name | Pascal Soriot | ||||
|---|---|---|---|---|---|
Work History | Roche Holding, and Genentech | ||||
Title | Chief Executive Officer | ||||
Status | Current |
Compare AstraZeneca to Competitors
Paige delivers AI-integrated digital diagnostics solutions and biomarkers for pathologists, oncologists, and the research and development community. It works with biopharma companies to create custom diagnostic solutions and drug development technologies to improve patient care. The firm's target customers include pathologists, hospital leads, and chairs as well as life sciences research and translational teams. The company was founded in 2017 and is based in New York, New York.
BRAVIS is a software and system house. It develops high-end internet-based video conference systems.
Seqirus is an influenza vaccine company with research and production capabilities and manufacturing plants in the US, UK, Germany and Australia.
HAPLN Science is a drug development company that focuses on anti-aging therapies that can reverse tissue and organ degeneration. The company's products include treatments for degenerative arthritis, skin aging treatment, hair loss, and connective tissue disease. HAPLN Science was founded in 2018 and is based in Seongnam, South Korea.
Syntr Health Technologies specializes in the micro fragmentation of adipose tissue for body contouring. The company was founded in 2016 and is based in Irvine, California.
Civica Rx is a not-for-profit generic drug company that will help patients by addressing shortages and high prices of lifesaving generic medications.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.